Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
about
Clinical use and applications of histone deacetylase inhibitors in multiple myelomaEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveDeacetylase inhibitors: an advance in myeloma therapy?Histone deacetylases and cardiovascular cell lineage commitment.Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.Panobinostat: first global approval.Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.Panobinostat for the management of multiple myeloma.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.HDACs and HDAC Inhibitors in Cancer Development and Therapy.Identification of early-stage lung adenocarcinoma prognostic signatures based on statistical modeling.Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitorsCurrent and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Evolutionary biology of high-risk multiple myeloma.Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemiaThe biological significance of histone modifiers in multiple myeloma: clinical applicationsThe Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
P2860
Q26745930-431239D9-151B-4594-A5AC-86BFEC7A4542Q26771331-20C5A6AE-AD08-494F-A4AD-7E79A32E4ADDQ28069789-B4D73DDF-1D0F-41FE-8A74-4222DCB63BDCQ33438321-86BE6726-C67F-47AF-BA54-4A1BF927DCC8Q35774293-B02F4FC1-FCB7-4B7E-95E9-4B90ED9BEDEAQ35876617-9ED20AF1-8D40-4266-B62A-8F20ECCD529CQ38403118-A76777FF-162D-4169-988F-30A4EC42EE21Q38435781-91635AE3-EE47-4606-B5CE-B49322865363Q38519497-16F07619-7196-4688-8063-2C2374987C61Q38616807-85732972-EDB6-47F0-B5C3-49FC4EBB4E83Q38716460-20AC0DA7-9A5C-479D-8F8E-6BB9BBF16722Q38806260-CB20F770-D175-48C2-A359-9DE3F3FB8B3BQ38853857-B32EF856-A359-4752-A5C3-EEB3E8990F4FQ38895512-250C312C-B98E-44F1-8B5B-5ED2F328855FQ38947405-E5A1BBD9-776E-49E9-B964-5AC915441B75Q39115659-A41406FB-3C15-4346-BB9F-1F40980E10CBQ39137683-378F9AEC-4D64-4539-8BDB-B5C801636D11Q39261435-1DBCC780-50B7-4D45-A2C3-8410D596D267Q39379624-A1B58084-A686-48E0-AE57-363285F777D6Q40424686-B4937D4F-5C59-43CE-8B68-C36E4D612DB3Q42316993-27350046-A90D-4FD7-B298-FACE9BE41378Q47348957-63EA161A-1697-41A3-AEC4-5930461B5598Q47913337-B1842A44-5702-4F28-993D-275DF2C385D8Q50649482-CC162DE6-F06C-4FFC-B260-616598DBC3CAQ52590685-71061485-BC38-458F-895C-C8B5CE8D8879Q55027177-C65AE587-CE07-4BEC-AB33-7DFAE555CAF5Q58699070-CA2E4BB8-F491-4505-83CE-986F83D977F0Q58718492-42793BCD-A3AE-4A37-B037-FADDA239FB32Q58792448-75356B29-0C06-4F2F-86D4-266A7CF8ACC3
P2860
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Dysregulated Class I histone d ...... prognosis in multiple myeloma.
@ast
Dysregulated Class I histone d ...... prognosis in multiple myeloma.
@en
type
label
Dysregulated Class I histone d ...... prognosis in multiple myeloma.
@ast
Dysregulated Class I histone d ...... prognosis in multiple myeloma.
@en
prefLabel
Dysregulated Class I histone d ...... prognosis in multiple myeloma.
@ast
Dysregulated Class I histone d ...... prognosis in multiple myeloma.
@en
P2093
P2860
P1433
P1476
Dysregulated Class I histone d ...... prognosis in multiple myeloma
@en
P2093
Andrew Spencer
Anna Kalff
Annie Chow
Tiffany Khong
P2860
P304
P356
10.4161/15592294.2014.983367
P577
2014-11-01T00:00:00Z